Physician profile
Amber Morton
NPI 1811352321
$8,997.65
in general payments reported to CMS, 2019-2025
41 companies · $997 in 2025
The $997 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,483 · 2022: $2,145 · 2023: $1,132 · 2024: $1,240 · 2025: $997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,369.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,489.82 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,345.21 | 2021-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $783.01 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $621.75 | 2021-2025 | Trintellix, Entyvio |
| Gilead Sciences, INC. | $528.55 | 2021-2023 | |
| Janssen Biotech, INC. | $473.38 | 2021-2023 | Stelara |
| Pfizer INC. | $411.00 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $409.97 | 2021-2023 | Linzess |
| Alnylam Pharmaceuticals INC. | $345.91 | 2021-2022 | |
| Redhill Biopharma INC. | $284.62 | 2021-2022 | |
| Lilly USA, LLC | $226.86 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Nestle Healthcare Nutrition INC. | $210.58 | 2021-2022 | |
| Qol Medical, LLC | $153.58 | 2021-2023 | Sucraid |
| Intercept Pharmaceuticals, INC. | $150.66 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $141.67 | 2024-2025 | Farxiga, Airsupra, Breztri |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $137.36 | 2021-2023 | Injectafer |
| Merck Sharp & Dohme LLC | $113.68 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Glaxosmithkline, LLC. | $102.59 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $95.32 | 2023-2025 | Spravato |
| Regeneron Healthcare Solutions, INC. | $90.93 | 2022-2023 | Dupixent |
| Lundbeck LLC | $89.99 | 2023-2025 | Vyepti |
| Astellas Pharma US INC | $89.94 | 2023-2025 | Veozah |
| Ardelyx, INC. | $74.31 | 2022-2024 | Ibsrela |
| Exact Sciences Corporation | $64.95 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Celgene Corporation | $60.82 | 2021-2023 | Zeposia |
| Amgen INC. | $58.46 | 2023-2025 | Repatha, Otezla, Repatha |
| Genzyme Corporation | $50.33 | 2022-2023 | |
| Evoke Pharma, INC. | $49.82 | 2021 | |
| Dexcom, INC. | $49.49 | 2024-2025 | Dexcom G6 Transmitter |
| Ferring Pharmaceuticals INC. | $47.35 | 2022-2023 | Rebyota |
| Otsuka America Pharmaceutical, INC. | $39.54 | 2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $38.77 | 2024-2025 | Voquezna |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28.23 | 2023 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $24.03 | 2025 | Sotyktu |
| Medtronic, INC. | $22.23 | 2025 | Synchromedii |
| Cranial Technologies, INC | $17.74 | 2025 | Doc Band |
| Abbott Laboratories | $16.20 | 2024 | Proclaim |
| Si-Bone, INC. | $16.20 | 2024 | |
| Idorsia Pharmaceuticals US INC | $15.75 | 2023 | Quviviq |
| Aimmune Therapeutics, INC. | $13.80 | 2024 | |
| Braintree Laboratories, INC. | $13.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Morton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.